Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment

NCT04524442 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT04524442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
Lead sponsor
Advanced Accelerator Applications
Phase
Phase 4
Overall status
Completed
Start date
January 25, 2021
Completion date
November 18, 2023
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine tumors